GPX4 and ovarian cancer: In p53 wild-type ovarian cancer cells, the anti-angiogenic agent apatinib synergizes with olaparib to downregulate GPX4 through dual suppression of nuclear factor erythroid 2-related factor 2 (NRF2) and autophagy pathways, eliciting ferroptosis (Yue et al., 2023).